U.S. Capital Wealth Advisors LLC Has $5.14 Million Stock Holdings in Novo Nordisk A/S $NVO

U.S. Capital Wealth Advisors LLC boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 93.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 92,695 shares of the company’s stock after purchasing an additional 44,707 shares during the quarter. U.S. Capital Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $5,144,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Revolve Wealth Partners LLC increased its position in shares of Novo Nordisk A/S by 8.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Novo Nordisk A/S by 15.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 261,243 shares of the company’s stock worth $18,141,000 after acquiring an additional 35,329 shares in the last quarter. Korea Investment CORP acquired a new position in Novo Nordisk A/S in the first quarter valued at about $2,666,000. Wellington Management Group LLP increased its holdings in shares of Novo Nordisk A/S by 23.0% in the first quarter. Wellington Management Group LLP now owns 1,021,707 shares of the company’s stock worth $70,947,000 after acquiring an additional 191,272 shares in the last quarter. Finally, Flow Traders U.S. LLC acquired a new stake in shares of Novo Nordisk A/S during the first quarter worth about $1,629,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of research reports. Argus reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a report on Tuesday, November 25th. Berenberg Bank raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Wednesday, September 17th. Rothschild & Co Redburn upgraded Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Finally, Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $53.33.

Novo Nordisk A/S Stock Up 1.0%

Shares of NVO stock opened at $48.10 on Friday. The firm’s fifty day moving average price is $49.84 and its two-hundred day moving average price is $57.59. The company has a current ratio of 0.78, a quick ratio of 0.57 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The firm has a market capitalization of $214.76 billion, a P/E ratio of 13.98 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo filed an NDA with the U.S. FDA for once‑weekly CagriSema, a next‑generation combination obesity injection that showed superior Phase III weight‑loss results — a potential major booster to its obesity franchise if approved. Article Title
• Positive Sentiment: Novo is pursuing a higher 7.2 mg Wegovy dose after data showed stronger weight loss — this could help reclaim share versus rivals (e.g., Eli Lilly’s Zepbound) if approved and commercialized effectively. Article Title
• Positive Sentiment: Analyst/commentary pieces highlight upside from oral Wegovy development, supply‑chain fixes and restructuring that could materially improve margins and growth if execution continues. Article Title
• Positive Sentiment: Kepler Capital initiated/maintained a buy view (reported coverage), giving some buy‑side support to the shares. Article Title
• Neutral Sentiment: UBS reiterated a Neutral (Hold) rating and left its price target unchanged, signaling continued caution on competitive pressures despite product progress. Article Title
• Neutral Sentiment: Commentary pieces are reassessing Novo’s valuation after a steep, year‑long share decline; some see a longer runway to recovery while others point to durable competitive threats. Article Title
• Negative Sentiment: Novo issued profit warnings and underwent a CEO change earlier this year and cut guidance, contributing to a large YTD share decline; that operational uncertainty remains a drag on investor confidence. Article Title
• Negative Sentiment: Shares recently dipped more than the broader market after earnings/profitability concerns were flagged; short‑term volatility is likely to persist as investors weigh approvals vs competitive share losses. Article Title

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.